XY 018
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584431

CAS#: 1873358-87-2

Description: XY 018 is a RORγ antagonist that suppresses androgen receptor expression in prostate cancer cell lines and inhibits growth of tumors in androgen receptor-positive xenograft models.


Price and Availability

Size
Price

10mg
USD 350
Size
Price

50mg
USD 990
Size
Price

XY 018, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584431
Name: XY 018
CAS#: 1873358-87-2
Chemical Formula: C23H15F7N2O4
Exact Mass: 516.092
Molecular Weight: 516.3718
Elemental Analysis: C, 53.50; H, 2.93; F, 25.75; N, 5.43; O, 12.39


Synonym: XY 018; XY018; XY-018

IUPAC/Chemical Name: N-[2'-Fluoro-4'-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl][1,1'biphenyl]-4-yl]-2-nitrobenzeneacetamide

InChi Key: MNVXADPCMINSEC-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H15F7N2O4/c24-18-12-15(21(34,22(25,26)27)23(28,29)30)7-10-17(18)13-5-8-16(9-6-13)31-20(33)11-14-3-1-2-4-19(14)32(35)36/h1-10,12,34H,11H2,(H,31,33)

SMILES Code: O=C(NC1=CC=C(C2=CC=C(C(C(F)(F)F)(O)C(F)(F)F)C=C2F)C=C1)CC3=CC=CC=C3[N+]([O-])=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

Wang et al (2016) ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat.Med. 22 488 PMID: 27019329

Ndagi et al (2016) Re-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer - a through conformational and binding analysis for RORγ protein. J.Biomol.Struct.Dyn. 36 1